Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “BORON”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 613 records · Page 34Linked to original sources
PubMed1996

Preparation and Characterization of Halogen-Boron-Phosphorus Compounds. X-ray Crystal Structures of X(3)B.P(SiMe(3))(3) and [X(2)BP(SiMe(3))(2)](2) (X = Cl, Br).

The 1:1 mole ratio reactions of boron trihalides (BX(3)) with tris(trimethylsilyl)phosphine [P(SiMe(3))(3)] produced 1:1 Lewis acid/base adducts [X(3)B.P(SiMe(3))(3), X = Cl (1), Br (2), I (5)]. Analogous 1:1 mole ratio reactions of these boron trihalides with lithium bis(trimethylsilyl)phosphide [LiP(SiMe(3))(2)] produced dimeric boron-phosphorus ring compounds {[X(2)BP(SiMe(3))(2)](2), X = Br (3), Cl (4)}. X-ray crystallographic studies were successfully conducted on compounds 1-4. Compound 1 crystallized in the orthorhombic space group Pbca, with a = 13.420(3) Å, b = 17.044(5) Å, c = 21.731(7) Å, V = 4970.6(25) Å(3), and D(calc) = 1.229 g cm(-3) for Z = 8; the B-P bond length was 2.022(9) Å, Compound 2 crystallized in the orthorhombic space group Pbca, with a = 13.581(6) Å, b = 17.106(7) Å, c = 22.021(9) Å, V = 5116(4) Å(3), and D(calc) = 1.540 g cm(-3) for Z = 8; the B-P bond length was 2.00(2) Å. Compound 3 crystallized in the monoclinic space group P2(1)/n, with a = 9.063(5) Å, b = 16.391(8) Å, c = 9.331(4) Å, V = 1379.2(12) Å(3), and D(calc) = 1.676 g cm(-3) for Z = 2; the B-P bond length was 2.023(10) Å. Compound 4 crystallized in the monoclinic space group P2(1)/n, with a = 9.143(5) Å, b = 16.021(8) Å, c = 9.170(4) Å, V = 1342.2(11) Å(3), and D(calc) = 1.282 g cm(-3) for Z = 2; the B-P bond length was 2.025(3) Å. Thermal decomposition studies were performed on compounds 1-4, yielding colored powders with boron:phosphorus ratios greater than 1:1 and significant C and H contamination indicated by elemental analyses.

Journal Article↗
PubMed2001

Light-harvesting and photocurrent generation by gold electrodes modified with mixed self-assembled monolayers of boron-dipyrrin and ferrocene-porphyrin-fullerene triad.

Three different kinds of mixed self-assembled monolayers have been prepared to mimic photosynthetic energy and electron transfer on a gold surface. Pyrene and boron-dipyrrin were chosen as a light-harvesting model. The mixed self-assembled monolayers of pyrene (or boron-dipyrrin) and porphyrin (energy acceptor model) reveal photoinduced singlet-singlet energy transfer from the pyrene (or boron-dipyrrin) to the porphyrin on the gold surface. The boron-dipyrrin has also been combined with a reaction center model, ferrocene-porphyrin-fullerene triad, to construct integrated artificial photosynthetic assemblies on a gold electrode using mixed monolayers of the respective self-assembled unit. The mixed self-assembled monolayers on the gold electrode have established a cascade of photoinduced energy transfer and multistep electron transfer, leading to the production of photocurrent output with the highest quantum yield (50 +/- 8%, based on the adsorbed photons) ever reported for photocurrent generation at monolayer-modified metal electrodes and across artificial membranes using donor-acceptor linked molecules. The incident photon-to-current efficiency (IPCE) of the photoelectrochemical cell at 510 and 430 nm was determined as 0.6% and 1.6%, respectively. Thus, the present system provides the first example of an artificial photosynthetic system, which not only mimics light-harvesting and charge separation processes in photosynthesis but also acts as an efficient light-to-current converter in molecular devices.

Journal Article↗
PubMed2005

Preparation and Suzuki-Miyaura coupling reactions of tetrahydropyridine-2-boronic acid pinacol esters.

[reaction: see text] A study on the conversion of lactam-derived vinyl triflates and phosphates into the corresponding vinyl boronates was carried out. While delta-valerolactam-derived vinyl triflates were successfully converted into 1,4,5,6-tetrahydropyridine-2-boronic acid pinacol ester derivatives by Pd-catalyzed coupling reaction with both bis(pinacolato)diboron and pinacolborane, pyrrolidinone and epsilon-caprolactam derivatives either did not react or were readily reduced. The delta-valerolactam-derived vinyl boronates are thermally stable compounds that efficiently coupled, under Pd catalysis, with structurally diverse aryl and heteroaryl bromides and triflates, vinyl iodides and bromides, and aromatic acid chlorides, to give the corresponding 2-substituted piperidines in good to excellent yields. The number of electrophiles that can virtually be coupled with these new boronic esters makes them very useful reagents for the synthesis of N-heterocyclic compounds.

Journal Article↗
PubMed2005

Optical transitions in single-wall boron nitride nanotubes.

Optical transitions in single-wall boron nitride nanotubes are investigated by means of optical absorption spectroscopy. Three absorption lines are observed. Two of them (at 4.45 and 5.5 eV) result from the quantification involved by the rolling up of the hexagonal boron nitride (h-BN) sheet. The nature of these lines is discussed, and two interpretations are proposed. A comparison with single-wall carbon nanotubes leads one to interpret these lines as transitions between pairs of van Hove singularities in the one-dimensional density of states of boron nitride single-wall nanotubes. But the confinement energy due to the rolling up of the h-BN sheet cannot explain a gap width of the boron nitride nanotubes below the h-BN gap. The low energy line is then attributed to the existence of a Frenkel exciton with a binding energy in the 1 eV range.

Journal Article↗
PubMed1998

The boron requirement and cell wall properties of growing and stationary suspension-cultured chenopodium album L. cells

Suspension-cultured Chenopodium album L. cells are capable of continuous, long-term growth on a boron-deficient medium. Compared with cultures grown with boron, these cultures contained more enlarged and detached cells, had increased turbidity due to the rupture of a small number of cells, and contained cells with an increased cell wall pore size. These characteristics were reversed by the addition of boric acid (>/=7 &mgr;M) to the boron-deficient cells. C. album cells grown in the presence of 100 &mgr;M boric acid entered the stationary phase when they were not subcultured, and remained viable for at least 3 weeks. The transition from the growth phase to the stationary phase was accompanied by a decrease in the wall pore size. Cells grown without boric acid or with 7 &mgr;M boric acid were not able to reduce their wall pore size at the transition to the stationary phase. These cells could not be kept viable in the stationary phase, because they continued to expand and died as a result of wall rupture. The addition of 100 &mgr;M boric acid prevented wall rupture and the wall pore size was reduced to normal values. We conclude that boron is required to maintain the normal pore structure of the wall matrix and to mechanically stabilize the wall at growth termination.

Journal Article↗
PubMed1969

Effect of light intensity and plant size on rate of development of early boron deficiency symptoms in tomato root tips.

Young tomato plants (Lycopersicon esculentum Miller, cultivar Rutgers) grown in solution culture at 27 degrees at 2 light intensities with adequate boron (0.1 mg/l) and treated with these 2 intensities in the absence of adequate boron developed root boron deficiency symptoms. The typical deficiency symptoms of decreased root elongation, increased depth of brown color and decreased RNA content of tips developed more rapidly at high than at low light intensity, and plant size influenced results. Plants supplied with adequate boron did not exhibit deficiency symptoms.

Journal Article↗
PubMed1980

Pyrimidine Pathway in Boron-deficient Cotton Fiber.

Cotton ovules cultured in an insufficiency of boron (10 micromolar), showed inhibition of fiber growth by the ninth day in culture. Averaging data from eight to eleven days of culture under these conditions, total incorporation of [6-(14)C]orotic acid into fiber was inhibited by 59%. Inhibition was evident in all radioactively labeled pools, indicating that the effect may be at the membrane transport level or at an early stage of orotic acid metabolism. On a per cent basis, incorporation into RNA under boron deficiency was higher than under sufficiency. The effect is greater on the eighth day of culture, with a decreasing difference from controls up to the eleventh day. Conversely, the per cent incorporation into UDP-glucose was lower under boron deficiency than in controls, having a more or less constant value from 8 to 11 days of culture. Thus, a primary event of boron deficiency in cotton fiber culture is an alteration in the flow of metabolites through the pyrimidine synthesis pathway.

Journal Article↗
PubMed1982

Role of boron in the far-red delay of nyctinastic closure of albizzia pinnules.

Boron has been found to be necessary for the delaying action of 710 nanometer irradiation on the nyctinastic closing of Albizzia julibrissin pinnules. It is effective only over a narrow micromolar range. In contrast, the delaying action of 470 nanometer irradiation on closure is inhibited by boron. The effect of boron on leaflet closing occurs rapidly. Boron is suggested to be involved in a phytochrome action that precedes and is required for a delaying effect on pinnule closing subsequently induced by an unknown far-red absorbing pigment.

Journal Article↗
PubMed1999

Boron nitride cones: structure determination by transmission electron microscopy.

A form of turbostratic boron nitride containing a large percentage of micrometre-size conically shaped particles was investigated by transmission electron microscopy. Electron diffraction patterns revealed the presence of correlations between adjacent boron nitride layers. The diffraction patterns were also used to determine the cone apex angle of many cone-like objects. The apex angles exhibited a broad distribution from 84 to 130 degrees with an ill defined peak in the 92-95 degrees region. These results could be accounted for by a structure model in which conical boron nitride layers are helically wound about a disclination axis, according to overlap angles that correspond to high densities of coincidental lattice sites between successive layers. The clustering of the apex angles near 93 degrees was attributed to the formation of a square ring during the nucleation stage. This appears to be specific to the boron nitride system.

Journal Article↗
PubMed2001

Superconductivity in boron.

Metals formed from light elements are predicted to exhibit intriguing states of electronic order. Of these materials, those containing boron are of considerable current interest because of their relatively high superconducting temperatures. We have investigated elemental boron to very high pressure using diamond anvil cell electrical conductivity techniques. We find that boron transforms from a nonmetal to a superconductor at about 160 gigapascals (GPa). The critical temperature of the transition increases from 6 kelvin (K) at 175 GPa to 11.2 K at 250 GPa, giving a positive pressure derivative of 0.05 K/GPa. Although the observed metallization pressure is compatible with the predictions of first-principles calculations, superconductivity in boron remains to be explored theoretically. The present results constitute a record pressure for both electrical conductivity studies and investigations of superconductivity in dense matter.

Journal Article↗
PubMed1996

Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy: biodistribution and toxicity in tumor-bearing mice.

Nickel-2,3,7,8,12,13,17,18-octaacetic acid-5,10,15,20-tetra-[3-carboranyl-methoxyphenyl]-porphyrin octamethylester (NiTCP) was given in a Cremophor EL, a polyethoxylated castor oil, and propylene glycol emulsion to BALB/c mice bearing transplanted s.c. KHJJ mammary carcinomas. A total dose of 244 microg NiTCP/gram body weight (gbw) (54 microg B/gbw) was given in 6 i.p. injections over a 32 hr period. Observations of behavior and changes in body weight and chemical and hematological blood tests indicated little or no toxicity from NiTCP over a period of 6-90 hr after injections. Boron concentrations near tumor margins were 160-180 microg B/g at 41-90 hr after the last injection. Tumor:normal brain boron concentration ratios reached approx. 10:1 and tumor:blood ratios reached approx. 250:1 after 4 days. There was no evidence of thrombocytopenia or other potentially important toxicities. Our findings place NiTCP among the leading candidates for pre-clinical experiments aimed toward improvement upon the compounds being tested for boron neutron-capture therapy of glioblastoma multiforme.

Alanine Transaminase↗
PubMed2003

Boronic acid compounds as potential pharmaceutical agents.

Boronic acid compounds have been used, because of their unique structural features, for the development of potent enzyme inhibitors, boron neutron capture agents for cancer therapy, and as antibody mimics that recognize biologically important saccharides. Consequently, there has been a surge of interests in boronic acid compounds. This study reviews the recent development in this area during the last six years.

Acids↗
PubMed1993

Boronate-containing polymer as novel mitogen for lymphocytes.

A novel water-soluble polymer (poly(AAm-co-PBA)) was synthesized by radical copolymerization of 3-acrylamidophenylboronic acid with acrylamide and evaluated as synthetic mitogen of lymphocytes. Boronic acid was introduced in the polymer as recognition site of sugar residues existing on the plasma membrane surface of lymphocyte, since it makes a covalent bonding with polyol compounds including sugars. Obvious increase in [3H]thymidine incorporation of lymphocytes was observed when murine spleen lymphocytes were cultured with poly(AAm-co-PBA), while little proliferative response of lymphocytes was observed in the presence of the homopolymer of acrylamide, the polymer without boronic acid moiety. This suggests that proliferation of lymphocytes was induced through the binding of phenylboronic acid moiety in poly(AAm-co-PBA) with glycoproteins existing on the plasma membrane surface of lymphocytes. Further, poly(AAm-co-PBA) was found to induce even the proliferation of B cell-depleted population of lymphocytes, suggesting T cell stimulation by this boronate-containing polymer.

Acrylic Resins↗
PubMedDate not supplied

Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation.

Development of any therapeutic modality can be facilitated by the use of the appropriate animal models to assess its efficacy. This report primarily will focus on our studies using the F98 and 9L rat glioma models to evaluate the effectiveness of boron neutron capture therapy (BNCT) of brain tumors. Following intracerebral implantation the biological behavior of each tumor resembles that of human high grade gliomas in a number of ways. In both models, glioma cells were implanted intracerebrally into syngeneic Fischer rats and approximately 10-14 days later BNCT was initiated at the Brookhaven National Laboratory Medical Research Reactor. Two low molecular weight (M(r) < 210Da) 10B-containing drugs, boronophenylalanine (BPA) and/or sodium borocaptate (BSH) were used as capture agents, either alone or in combination with each other. The 9L gliosarcoma, which has been difficult to cure by means of either chemo- or radiotherapy alone, was readily curable by BNCT. The best survival data were obtained using BPA at a dose of 1200 mg/kg (64.8mg 10B), administered intraperitoneally (i.p.), with a 100% survival rate at 8 months. In contrast, the F98 glioma has been refractory to all therapeutic modalities. Tumor bearing animals, which had received 500 mg/kg (27 mg 10B) of BPA, or an equivalent amount of BSH i.v., had mean survival time (MST) of 37 and 33 days, respectively, compared to 29 days for irradiated controls. The best survival data with the F98 glioma model were obtained using BPA + BSH in combination, administered intra-arterially via the internal carotid artery (i.c.) with hyperosmotic mannitol induced blood-brain barrier disruption (BBB-D). The MST was 140 days with a cure rate of 25%, compared to a MST of 73 days with a 5% cure rate without BBB-D, and 41 days following i.v. administration of both drugs. A modest but significant increase in MST also was observed in rats that received intracarotid (i.c.) BPA in combination with Cereport (RMP-7), which produced a pharmacologically mediated opening of the BBB. Studies also have been carried out with the F98 glioma to determine whether an X-ray boost could enhance the efficacy of BNCT, and it was shown that there was a significant therapeutic gain. Finally, molecular targeting of the epidermal growth factor receptor (EGFR) has been investigated using F98 glioma cells, which had been transfected with the gene encoding EGFR and, intratumoral injection of boronated EGF as the delivery agent, followed by BNCT. These studies demonstrated that there was specific targeting of EGFR and provided proof of principle for the use of high molecular weight, receptor targeting-boron delivery agents. Finally, a xenograft model for melanoma metastatic to the brain has been developed using a human melanoma (MRA27), stereotactically implanted into the brains of nude rats, and these studies demonstrated that BNCT either cured or significantly prolonged the survival of tumor-bearing rats. It remains to be determined, which, if any, of these experimental approaches will be translated into clinical studies. Be that as it may, rat brain tumor models already have made a significant contribution to the design of clinical BNCT protocols, and should continue to do so in the future.

Animals↗
PubMedDate not supplied

Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams.

Our concept of boron neutron capture therapy (BNCT) is selective destruction of tumor cells using the heavy-charged particles yielded through 10B(n, alpha)7 Li reactions. To design a new protocol that employs epithermal neutron beams in the treatment of glioma patients, we examined the relationship between the radiation dose, histological tumor grade, and clinical outcome. Since 1968, 183 patients with different kinds of brain tumors were treated by BNCT; for this retrospective study, we selected 105 patients with glial tumors who were treated in Japan between 1978 and 1997. In the analysis of side effects due to radiation, we included all the 159 patients treated between 1977 and 2001. With respect to the radiation dose (i.e. physical dose of boron n-alpha reaction), the new protocol prescribes a minimum tumor volume dose of 15 Gy or, alternatively, a minimum target volume dose of 18 Gy. The maximum vascular dose should not exceed 15 Gy (physical dose of boron n-alpha reaction) and the total amount of gamma rays should remain below 10 Gy, including core gamma rays from the reactor and capture gamma in brain tissue. The outcomes for 10 patients who were treated by the new protocol using a new mode composed of thermal and epithermal neutrons are reported.

Adolescent↗
PubMedDate not supplied

Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden.

A boron neutron capture therapy (BNCT) facility has been constructed at Studsvik, Sweden. It includes two filter/moderator configurations. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range. The other beam has been designed to produce a large uniform field of thermal neutrons for radiobiological research. Scientific operations of the Studsvik BNCT project are overseen by the Scientific Advisory Board comprised of representatives of major universities in Sweden. Furthermore, special task groups for clinical and preclinical studies have been formed to facilitate collaboration with academia. The clinical Phase II trials for glioblastoma are sponsored by the Swedish National Neuro-Oncology Group and, presently, involve a protocol for BNCT treatment of glioblastoma patients who have not received any therapy other than surgery. In this protocol, p-boronophenylalanine (BPA), administered as a 6-h intravenous infusion, is used as the boron delivery agent. As of January 2002, 17 patients were treated. The 6-h infusion of 900 mg BPA/kg body weight was shown to be safe and resulted in the average blood-boron concentration of 24 microg/g (range: 15-32 microg/g) at the time of irradiation (approximately 2-3 h post-infusion). Peak and average weighted radiation doses to the brain were in the ranges of 8.0-15.5 Gy(W) and 3.3-6.1 Gy(W), respectively. So far, no severe BNCT-related acute toxicities have been observed. Due to the short follow-up time, it is too early to evaluate the efficacy of these studies.

Adult↗
PubMed1996

Fast neutron radiotherapy and boron neutron capture therapy: application to a human melanoma test system.

Fast neutron radiotherapy has proven to be an effective form of treatment in a selected subset of tumors (salivary gland tumors, sarcomas, and locally-advanced prostate cancer), but has not proven to be more beneficial than conventional photon irradiation for the majority of tumor types upon which it has been tested. Normal tissue tolerance limits preclude simply further escalating the neutron dose. Boron neutron capture (BNC) provides a way of selectively augmenting the radiation dose to the tumor. This process is described, and cell culture and animal model data reviewed. An irradiation configuration was developed where an enhancement of 2.10(-3) for 1 microgram of 10B per gram of tissue was achieved. This is similar to the enhancement achievable in the center of a 20 x 20 cm field envisioned for future applications such as metastases in the brain. A boron concentration of 50 micrograms per gram of tumor tissue leads to a 10% increase in the delivered physical dose in this scenario. The first human test of BNC enhancement of a fast neutron radiotherapy beam using pharmacologically-acceptable doses of orally-administered, 10B-enriched, L-paraboronophenylalanine is reported. An enhancement of tumor response was demonstrated for a melanoma skin nodule test system. Boron levels achieved in blood, skin, and tumors are presented. Future research plans are discussed.

Administration, Oral↗
PubMed2004

Boron neutron capture therapy for undifferentiated thyroid carcinoma: preliminary results with the combined use of BPA and BOPP.

We have shown the selective uptake of borophenylalanine (BPA) by undifferentiated human thyroid cancer (UTC) ARO cells both in vitro and in vivo. Moreover, a 50% histologic cure of mice bearing the tumor was observed when the complete boron neutron capture therapy was applied. More recently we have analyzed the biodistribution of BOPP (tetrakis-carborane carboxylate ester of 2,4-bis-(alpha,beta-dihydroxyethyl)-deutero-porphyrin IX) and showed that when BOPP was injected 5 days before BPA, and the animals were sacrificed 60 min after the i.p. injection of BPA, a significant increase in boron uptake by the tumor was found (38-45 ppm with both compounds vs. 20 ppm with BPA alone). Five days post the i.p BOPP injection and 1h after BPA the ratios were: tumor/blood 3.75; tumor/distal skin 2. Other important ratios were tumor/thyroid 6.65 and tumor/lung 3.8. The present studies were performed in mice transplanted with ARO cells and injected with BOPP and BPA. Only in mice treated with the neutron beam and injected with the boronated compounds we observed a 100% control of tumor growth. Two groups of mice received different total absorbed doses: 3.00 and 6.01 Gy, but no further improvement in the outcome was found compared to the previous results using BPA alone (4.3 Gy).

Animals↗